|  | Emmprin |  |
---|---|---|---|
   Variable | Numbers | mean ± SE | p-value |
Age (years) | Â | Â | 0.445 |
<60 | 80 | 1.38 ± 0.70 |  |
≥60 | 54 | 1.48 ± 0.84 |  |
FIGO stage | Â | Â | 0.009* |
I-II | 85 | 1.30 ± 0.65 |  |
III-IV | 49 | 1.61 ± 0.67 |  |
Histology | Â | Â | 0.017* |
Type I (G1 + G2) | 106 | 1.34 ± 0.69 |  |
Type II (G3 + carcinosarcoma) | 28 | 1.68 ± 0.54 |  |
Depth of myometrial invasion | Â | Â | 0.001* |
<1/2 | 87 | 1.28 ± 0.66 |  |
≥1/2 | 47 | 1.66 ± 0.63 |  |
Cervical involvement | Â | Â | 0.001* |
Negative | 105 | 1.32 ± 0.67 |  |
Positive | 29 | 1.75 ± 0.57 |  |
Lymph node metastasis | Â | Â | <0.001* |
Negative | 116 | 1.34 ± 0.67 |  |
Positive | 18 | 1.89 ± 0.47 |  |
LVS involvement | Â | Â | <0.001* |
Negative | 90 | 1.27 ± 0.67 |  |
Positive | 44 | 1.70 ± 0.59 |  |
Ovarian metastasis | Â | Â | 0.127 |
Negative | 119 | 1.38 ± 0.66 |  |
Positive | 15 | 1.66 ± 0.72 |  |
Peritoneal cytology | Â | Â | 0.031* |
Negative | 105 | 1.35 ± 0.67 |  |
Positive | 29 | 1.65 ± 0.61 |  |